Capitan Orthopedics closes oversubscribed seed round

What's the deal? Capitan OrthopedicsDealroom has a profile for this one. Try Dealroom → has closed an oversubscribed seed round, taking its total capital raised to date to $4.1 million. Genesis Innovation GroupDealroom has a profile for this one. Try Dealroom → backs the company.

Why now? Capitan Orthopedics plans to use the funds for project development and validation and to begin its first in-human clinical trial, expected in Q1 2027. The company is developing the SupraSpacer implant for younger, active patients with irreparable rotator cuff tears.

Read more: PR Newswire